ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Methylphenidate modulates the ınflammatory response and PI3K signaling in macrophages.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study explored the potential immunomodulatory role of methylphenidate (MPH), specifically focusing on its modulation of the inflammatory response and the phosphoinositide 3-kinase (PI3K) signaling pathway in J774.2 murine macrophages. Cells were treated with increasing concentrations of MPH (1, 5, and 10 μg/mL) in the presence or absence of lipopolysaccharide (LPS). Cytokine concentrations (TNF-α, IL-6, IL-12p40, and GM-CSF) were quantified using ELISA, and intracellular activation of the PI3K signaling pathway was assessed via flow cytometry. It was demonstrated that MPH strongly suppressed the inflammatory cytokines TNF-α, IL-6, and IL-12p40 in a dose-dependent manner (p < 0.001), with significant suppression of GM-CSF evident at higher doses. Furthermore, flow cytometric analysis revealed that PI3K signaling was modulated in the presence of LPS, indicating a complex regulatory mechanism. Collectively, these findings suggest that MPH holds therapeutic potential for neuroinflammatory disorders through the dual action of suppressing inflammatory cytokines and modulating PI3K signaling pathways.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.